

There is nothing easy about launching a biotech company. Even for the most experienced entrepreneurs, the capital costs are significant, the state licensing and permitting is challenging, and the chances of success are not great.



30 early-stage companies, employing 118+

Entrepreneurship is a way of life. At LabCentral, we offer space to early-stage life-science companies that fits their needs and increases the likelihood of success. When startup companies are successful, they create jobs, grow our economy, and provide new solutions to human health problems that just a generation ago, were unimaginable.

By the end of our first full year of operation in December 2014, LabCentral has been home to 30 resident companies. That's 15 more than we expected to service in our first year of operation.

Consistent with LabCentral's mission, resident companies were selected for high potential and high impact. Companies are required to have raised less than \$7.5 million in financing when they move in, but since then, LabCentral residents have raised more than \$200 million dollars in financing for their businesses and research and are quickly becoming leaders in the Cambridge startup community.

LabCentral's growth has been in large part due to the continued support from sponsors. In addition to the initial \$4.9 million capital grant, LabCentral has secured more than \$19.5 million in sponsorship commitments.


We are incredibly grateful for the support we've received and look forward to continuing to provide early-stage companies the best place to grow in coming years!



New employees: 60 new scientists, 19.5 executives & administrative employees in 2014

79.5 new jobs created by resident companies

2014 VENTURE CAPITAL INVESTMENT IN EARLY & SEED-STAGE LIFE-SCIENCE & BIOTECHNOLOGY COMPANIES



21 licensing agreements made



90 trainings & events offered; 2,000+ in attendance



57 new patents filed



22 new partnerships formed; four among LabCentral Companies



28,234 cups of coffee consumed (2,161,430 mg caffeine)



Application & Selection

We select high-potential, high-impact companies from those that apply. Of 150 applicants in 2014, we accepted just 20%.

Residency

Once on site, companies receive access to more than \$3 M in lab equipment, operational and lab support, work space, conference rooms, 8 to 12 trainings per month, a strong network and many additional resources.

Moving Out

Companies stay an average of 15 to 18 months as they mature. Throughout this process they receive assistance from LabCentral staff and sponsors in transitioning to their own space. Three companies are prepped to graduate in Q1 of 2015.


Continued Growth

Alumni expand their company once outside of our walls, while remaining a part of our community, receiving ongoing training, perks, and networking opportunities.

*all financial and investment data self-reported by LabCentral resident companies. Comparative VC data taken from PWC Money Tree and Swiss Private Equity & Corporate Finance Association



Source of all LabCentral
Resident Company Funding



2014 Board of Directors

Johannes Fruehauf, MD, PhD (Co-Founder, President)
CEO, Cambridge Biolabs and ViThera Pharma; Co-Founder, Cequent Pharma

John Harthorne
CEO, MassChallenge; Bain & Company

Peter Parker (Co-Founder)
CEO, BioInnovation; Partner, Ampersand Ventures; Founder, Boston Heart Dx;
CEO, Cequent Pharma, Deltix

Tim Rowe (Co-Founder, Chairman)
CEO, Cambridge Innovation Center; Venture Partner, New Atlantic Ventures

Steve Tregay
CEO, Forma Therapeutics; Novartis Venture Fund; Novartis Strategic Alliances

2014 Sponsors

Founding



Platinum



Gold



Sponsors



IMPACT REPORT 2014

Lab | Central

700 Main Street, North
Cambridge, MA 02139
617-863-3650
info@labcentral.org
www.labcentral.org

Lab | Central